| 生物活性 |
KHS101 is a blood-brain barrier-penetrant anticancer agent that functions primarily by inhibiting HSPD1 (IC50 = 14.4 μM) and TACC3 in different cellular contexts; it promotes HSPD1 aggregation with client proteins, destabilizes TACC3, reduces TACC3, Aurora A, and PLK1 levels, and induces autophagy, apoptosis, cell cycle exit, and neuronal differentiation, while inhibiting cancer cell growth, motility, EMT, and stemness, and also impairing mitochondrial bioenergetics and glycolysis in glioblastoma cells, making it useful for research on glioblastoma multiforme and breast cancer. |
体外研究 (In Vitro) |
KHS101 (0-20 μM; 5 days) 可在全部 6 株患者来源 GBM 细胞系以及 U251/U87 细胞中诱导剂量依赖性细胞毒性,作用 5 天后的 IC50 值分别为:GBM1 细胞 2.23 μM、GBM4 细胞 0.97 μM、GBM11 细胞 5.05 μM、GBM13 细胞 3.28 μM、GBM14 细胞 1.98 μM、GBM20 细胞 1.87 μM。 KHS101 (1-7.5 μM; 12 h) 处理 12 小时后,可在患者来源的人胶质母细胞瘤 (GBM) 细胞系 (GBM1、GBM4、GBM11、GBM13、GBM14、GBM20) 中选择性诱导浓度依赖性自噬,而在非癌性 NP1 神经祖细胞中无可见作用。 KHS101 (7.5 μM; 48 h) 选择性地在患者来源的人 GBM 细胞系 (GBM1、GBM11、GBM20) 中诱导时间依赖性凋亡,而对非癌变的 NP1 神经前体细胞的影响极小,且该凋亡不依赖于晚期自噬。 KHS101 (7.5 μM) 可选择性破坏患者来源的人 GBM 细胞系的代谢表型,诱导代谢活性发生显著的缺氧转变,而在以 7.5 μM 进行急性处理后,对非癌细胞系 (NP1, NP2, NHAs) 仅造成极微小的糖酵解变化。 KHS101 (7.5 μM; 4-24 h) 选择性地损伤患者来源的人 GBM1 细胞的有氧糖酵解与三羧酸 (TCA) 循环活性,减少葡萄糖来源的碳向关键代谢中间产物的掺入,并在 24 小时后使细胞总 ATP 水平降低 ≥ 50%;而该药物在非癌细胞 NP1 神经祖细胞中无此类作用。 KHS101 (7.5 μM; 1 h) 选择性诱导患者来源的人 GBM1 细胞中 HSPD1 和关键代谢酶发生聚集,而在非癌性 NP1 神经祖细胞中仅观察到极少量聚集。 KHS101 (10-100 μM; 24 h) 以与 TACC3 表达相关的方式抑制 MDA-MB-231、MDA-MB-468 和 MCF7 乳腺癌细胞的增殖,其中 20 μM 可选择性抑制乳腺癌细胞生长,且不影响非致瘤性乳腺上皮细胞 MCF10A。 KHS101 (5-20 μM; 24 h) 在 20 μM 浓度下可降低 MDA-MB-231 和 SKBR3 乳腺癌细胞中的 TACC3 蛋白水平,但处理 24 h 后不会改变 MDA-MB-468 和 BT549 乳腺癌细胞中的 TACC3 水平。 KHS101 (5-20 μM; 7 days) 可抑制 MDA-MB-468 和 SKBR3 乳腺癌细胞的乳腺球形成,并降低其乳腺球形成效率。 KHS101 (5-20 μM; 24 h) 可降低 MDA-MB-231 乳腺癌细胞中 Oct4、Sox2 和 Nanog 干细胞标志物的 mRNA 表达水平。 KHS101 (20 μM; 24 h) 可降低 MDA-MB-231 乳腺癌细胞中间质标志物 (N-cadherin、Vimentin) 以及干性标志物 CD44 的蛋白表达水平。 KHS101 (20 μM; 24 h) 可降低 MDA-MB-231 乳腺癌细胞中 Snail、Slug 和 Twist 这些 EMT 转录因子的 mRNA 表达水平。 KHS101 (20-60 μM; 16 h) 抑制 MDA-MB-231 和 MDA-MB-468 乳腺癌细胞的迁移。 KHS101 (20 μM; 24 h) 可在 20 μM 处理 24 h 后抑制 MDA-MB-231 和 MDA-MB-468 乳腺癌细胞的侵袭。 KHS101 (20 μM; 24-72 h) 可在 20 μM 处理 24、48 和 72 h 后增加 MDA-MB-231 和 MDA-MB-468 乳腺癌细胞中的亚 G1 期凋亡细胞群,且对整体细胞周期分布具有细胞类型特异性作用。 KHS101 (20 μM; 24-72 h) 可在 20 μM 浓度下处理 24、48 和 72 h 后,诱导 MDA-MB-231 和 MDA-MB-468 乳腺癌细胞发生时间依赖性凋亡,且对 MDA-MB-468 细胞的作用更强。 KHS101 (20 μM) 可改变 MDA-MB-468 乳腺癌细胞的全局蛋白质组谱,参与催化活性、结合作用、代谢过程、细胞过程以及多种癌症相关信号通路的蛋白质发生显著变化。 KHS101 (20 μM; 24 h) 可降低 MDA-MB-468、SKBR3 和 MCF7 乳腺癌细胞中 Aurora A 和 PLK1 有丝分裂激酶的蛋白表达。 KHS101 (0.6-5 μM; 1-12 d) 可剂量依赖性地诱导贴壁培养的成年大鼠海马神经前体细胞 (NPCs) 发生神经元分化,其 EC50 约为 1 μM;在 5 μM 浓度下作用 12 天可生成功能性成熟神经元。 KHS101 (1.5-5 μM; 4 d) 可诱导成年大鼠海马体和 SVZ 神经前体细胞 (NPCs) 来源的次级神经球发生神经元分化,在 1.5-5 μM 作用 4 天的条件下,有 40%-60% 的细胞成为 TuJ1 阳性神经元。 KHS101 (0.6-5 μM; 4 d) 可剂量依赖性地抑制 BMP4 诱导的成年大鼠海马神经前体细胞 (NPCs) 向星形胶质细胞分化,并促进其向神经元分化。 KHS101 (0.6-5 μM; 24 h-72 h) 呈剂量依赖性上调 Cdkn1 的表达,并抑制成年大鼠海马神经前体细胞 (NPCs) 的增殖及有丝分裂活性;在 5 μM 作用 72 小时后,Ki67 阳性细胞数量显著降低。 KHS101 (5-15 μM; 12-24 h) 可在异位表达的 293T 细胞及成年大鼠海马神经前体细胞 (NPCs) 中增强 ARNT2 的核定位。
Cell Autophagy Assay
| Cell Line: |
Patient-derived human GBM cell lines (GBM1, GBM4, GBM11, GBM13, GBM14, GBM20), noncancerous adult brain neural progenitor (NP1) cell line |
| Concentration: |
1 μM, 2.5 μM, 7.5 μM |
| Incubation Time: |
12 h |
| Result: |
Induced pronounced intracellular vacuole development and increased LC3B-positive autophagosomal compartments in GBM1 cells compared to NP1 cells and vehicle-treated controls after 12 hours of treatment with 7.5 μM. Increased LC3B staining in all tested GBM cell lines, while NP1 cells showed no such increase. Caused concentration-dependent increase in LC3B-positive cytoplasmic area in GBM1, GBM11, and GBM20 cells after 12 hours, with the highest response at 7.5 μM. Increased CYTO-ID positive cells in GBM1 cells in a concentration-dependent manner, with > 80% of cells positive after 12 hours of treatment with 7.5 μM. |
Apoptosis Analysis
| Cell Line: |
Patient-derived human GBM cell lines (GBM1, GBM4, GBM11, GBM13, GBM14, GBM20), noncancerous adult brain neural progenitor (NP1) cell line |
| Concentration: |
7.5 μM |
| Incubation Time: |
48 h |
| Result: |
Induced a time-dependent increase in caspase 3/7 activation in GBM1 cells over 50 hours, with significantly higher activation than vehicle controls at the 48-hour time point. Caused marked increases in relative caspase 3/7 activation in GBM1, GBM11, and GBM20 cells compared to NP1 cells after 48 hours of treatment with 7.5 μM. Induced significant accumulation of annexin V-positive apoptotic cells in GBM1 cells 48 hours after treatment, and this apoptotic cell death was not prevented by chemical inhibition of late-stage autophagy. |
Cell Proliferation Assay
| Cell Line: |
MCF10A non-tumorigenic human mammary epithelial cells, MDA-MB-231, MDA-MB-468, and MCF7 breast cancer cells |
| Concentration: |
10, 20, 40, 60, 80, 100 μM |
| Incubation Time: |
24 h |
| Result: |
Showed breast cancer cells (MDA-MB-231, MDA-MB-468, MCF7) were more sensitive to KHS101 than MCF10A cells, with proliferation inhibition correlated to endogenous TACC3 expression. Revealed MDA-MB-231 and MDA-MB-468 (high TACC3) showed greater sensitivity than MCF7 (low/undetectable TACC3). Suppressed breast cancer cell growth at 20 μM but did not affect MCF10A cell growth. |
Western Blot Analysis
| Cell Line: |
MDA-MB-231, MDA-MB-468, SKBR3, and BT549 breast cancer cells |
| Concentration: |
5, 10, 20 μM |
| Incubation Time: |
24 h |
| Result: |
Significantly reduced TACC3 protein levels at 20 μM in MDA-MB-231 and SKBR3 cells. Showed no significant change in TACC3 levels in MDA-MB-468 and BT549 cells. |
Real Time qPCR
| Cell Line: |
MDA-MB-231 breast cancer cells |
| Concentration: |
5, 10, 20 μM |
| Incubation Time: |
24 h |
| Result: |
Reduced mRNA expression of stem cell markers Oct4, Sox2, and Nanog in a concentration-dependent manner. Showed all tested concentrations significantly decreased marker expression relative to control. |
Western Blot Analysis
| Cell Line: |
MDA-MB-468 and MDA-MB-231 breast cancer cells |
| Concentration: |
20 μM |
| Incubation Time: |
24 h |
| Result: |
Reduced protein expression of mesenchymal markers N-cadherin and Vimentin, and stemness marker CD44 in MDA-MB-231 cells. Found MDA-MB-468 cells showed undetectable N-cadherin and CD44 levels, and reduced TACC3 expression. |
Real Time qPCR
| Cell Line: |
MDA-MB-231 breast cancer cells |
| Concentration: |
20 μM |
| Incubation Time: |
24 h |
| Result: |
Significantly reduced mRNA expression of EMT transcription factors Snail, Slug, and Twist relative to control. |
Cell Migration Assay
| Cell Line: |
MDA-MB-231 and MDA-MB-468 breast cancer cells |
| Concentration: |
20, 40, 60 μM |
| Incubation Time: |
16 h |
| Result: |
Reduced relative migration of MDA-MB-231 and MDA-MB-468 cells in a concentration-dependent manner. Showed all tested concentrations significantly decreased migration relative to control. |
Cell Invasion Assay
| Cell Line: |
MDA-MB-231 and MDA-MB-468 breast cancer cells |
| Concentration: |
20 μM |
| Incubation Time: |
24 h |
| Result: |
Significantly reduced relative invasion of MDA-MB-231 and MDA-MB-468 cells relative to control. |
Cell Cycle Analysis
| Cell Line: |
MDA-MB-231 and MDA-MB-468 breast cancer cells |
| Concentration: |
20 μM |
| Incubation Time: |
24, 48, 72 h |
| Result: |
Induced cell cycle distribution changes in a cell type-dependent manner. Significantly increased the sub-G1 population (a marker of apoptotic cells) in both MDA-MB-231 and MDA-MB-468 cells in a time-dependent manner. |
Apoptosis Analysis
| Cell Line: |
MDA-MB-231 and MDA-MB-468 breast cancer cells |
| Concentration: |
20 μM |
| Incubation Time: |
24, 48, 72 h |
| Result: |
Increased the percentage of apoptotic cells in both MDA-MB-231 and MDA-MB-468 cells in a time-dependent manner. Found MDA-MB-468 cells showed a greater magnitude of apoptotic induction than MDA-MB-231 cells. |
Western Blot Analysis
| Cell Line: |
MDA-MB-468 and MDA-MB-231 breast cancer cells |
| Concentration: |
20 μM |
| Incubation Time: |
24 h |
| Result: |
Significantly reduced protein expression of mitotic kinases Aurora A and PLK1 in MDA-MB-468, SKBR3, and MCF7 cells, regardless of endogenous TACC3 expression levels. |
|